Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

/in

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1 This breakthrough innovation represents a major milestone in Neuraxpharm’s commitment to advancing both digital and personalised solutions that enhance safety and improve quality of life […]

Read more

Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed with antimicrobials to treat infection

/in

STIMULAN® Rapid Cure can now be used with both a wider range of antibiotics and also with antifungals in India STIMULAN® Rapid Cure can be placed in bone and surrounding soft tissue to assist in wound healing and treatment of infection Keele, UK, 25 November 2025 – Biocomposites, an international medical devices company that engineers, […]

Read more

Poolbeg Pharma plc – POLB 001 European Patent granted

/in

Further strengthens Poolbeg’s global intellectual property portfolio 20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read more…

Read more

Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals

/in

Total capital raised across Sofinnova’s platform reaches €1.5Bn over the past year Sofinnova Capital XI is actively investing in early-stage biotech and medtech companies across Europe and the US PARIS, France – November 17, 2025 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the close of […]

Read more

Medicxi Announces €500 Million Fund V

/in

New fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The […]

Read more
© Optimum Strategic Communications.